UK Supreme Court strikes down Regeneron patents, opening door for Kymab
The UK Supreme Court has struck down a pair of Regeneron patents, all but ending a legal dispute between the large US biotech and an upstart British competitor that has raged since 2013.
In a 4-1 ruling, the judges held that the patents Regeneron filed on a technique necessary to make their antibody-producing mice didn’t provide enough information for an expert in the field to reproduce all the inventions covered in the claim. The ruling overturned an appellate court decision that held in favor of Regeneron and against the Cambridge-based Kymab.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.